Nuhey News

We talk about the MARKET

Human Prothrombin Complex Market is Expected to Clock a Notable 11.8% CAGR During the 2022-2028

Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.

Due to the COVID-19 pandemic, the global Human Prothrombin Complex market size is estimated to be worth US$ 1577 million in 2021 and is forecast to a readjusted size of US$ 3473.8 million by 2028 with a CAGR of 11.8% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Human Prothrombin Complex market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Human Prothrombin Complex landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Human Prothrombin Complex key players include Octapharma, Shire, CSL, etc. Global top three manufacturers hold a share over 75%.

North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.

In terms of product, 500 IU/Vial is the largest segment, with a share over 50%. And in terms of application, the largest application is Hemophilia B, followed by Vitamin K Deficiency, etc.

This report focuses on Human Prothrombin Complex volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Human Prothrombin Complex market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Request for a free sample or purchase this report at:

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • 500 IU/Vial
  • 600 IU/Vial
  • 1000 IU/Vial
  • Others

Segment by Application

  • Hemophilia B
  • Vitamin K Deficiency
  • Others

By Company

  • Takeda
  • Csl
  • Grifols
  • Octapharma
  • Hualan Biological
  • Meheco Xinxing Pharma

Production by Region

  • North America
  • Europe
  • China

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)


Contact Details:

Mr. Shirish Gupta

Sales Manager

The Market Reports | Industry and Market Reports at its Best

Call: +1-631-407-1315 / +91-750-729-1479